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ABSTRACT 
Psoralea corylifolia is used for treatmet of skin diseases such as psoriasis, vitiligo. Psoralen is responsible for its effectiveness against psoriasis. 
Bakuchicin and Bakuchiol are DNA polymerase and topoisomerase II inhibitors. To study the effect of pH and gastrointestinal (GI) enzymes on 
Psoralen, Bakuchicin and Bakuchiol from Psoralea corylifolia Linn using a simple, sensitive, accurate and robust high performance thin layer 
chromatographic (HPTLC) method. The method was performed on silica gel 60 F254with n- Hexane : Ethyl acetate ( 7.5 : 2.5 v/v)  as the mobile 
phase. Densitometric scanning at 285 nm for Psoralen, Bakuchicin and Bakuchiol was used. The method was validated as per the guidelines of 
International Conference on Harmonization (ICH). In addition the applicability of the method was tested for the standardization of both mono 
and polyherbal formulations containing the above markers. The Rf values of 0.37, 0.48 and 0.63 were obtained for Psoralen, Bakuchicin and 
Bakuchiol respectively. The linearity range of 20-120 ng spot-1,  20-120 ng spot-1 and 80-280 ng spot-1  with good correlation coefficients of r2 = 
0.998, 0.998 and 0.999 were obtained for Psoralen, Bakuchicin and Bakuchiol  respectively. The method was applied for the in vitro stability 
studies of above markers in simulated gastric and intestinal fluids to study the effect of pH and GI enzymes.  Psoralen was found to be most 
stable in the simulated physiological fluids whereas other two compounds showed instability. The method was found to be precise, robust and 
suitable for the routine quality control analysis of plant extracts and polyherbal formulations. 
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Abbreviations :   
P.corylifolia: Psoralea corylifolia 
SGF : Simulated Gastric Fluid 
SIF : Simulated Intestinal Fluid 
HPTLC : High performance thin layer chromatography 
ICH : International Conference on Harmonization 
GI : Gastro Intestinal 
1. INTRODUCTION   
Psoralea corylifolia Linn. (Fam: leguminoceae) is the most 
popular herb used in Indian traditional medicines since 
ancient time. It has been officially listed in Chinese 
Pharmacopoeia1. The different parts of the plant such as 
seeds, seed oil, roots and leaves are used for therapeutic 
effects 2.  The plant is widely exploited since ages for its 
effect against several skin diseases, such as psoriasis, 
leukoderma, and leprosy3. It also possess anthelmintic, 
laxative, diuretic, aphrodiasic, antipyretic, analgesic, anti-
staphylococeal and antifungal activity 4,5,6.    
Psoralea corylifolia Linn contains wide variety of 
phytochemicals such as   Psoralen, Angelicin, Bakuchiol, 
Psoralidin, Isopsoralen  7,8,9 etc. The flavonoids present in 
the seed are Corylifolin, Bakuchicin, Psoralidin, Bavachin, 
Corylifolinin, Bavachinin Corylin, Corylidin 10,11,12,13  
Psoralen (Fig.1a) bakuchicin (Fig 1b) and bakuchiol (Fig 1c) 
are considered to be the main constituents responsible for 
pharmacological activities of the plant. 
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Fig. 1. Structure of Bakuchicin, Bakuchiol and Psoralen 
 
Psoralen is responsible for inducing pigmentation of skin. It 
is used to treat skin diseases such as psoriasis and vitiligo, 
renal weakness and other kidney dysfunctions 14. Estimation 
of Psoralen from natural herbs and herbal products is done 
by different analytical methods like HPLC 14,15,16, TLC 17 , 
HPTLC 18, Micellar Electrokinetic Capillary 
Chromatography19, LC- Electrospray ionization mass 
spectrometry20.  
Bakuchicin, a furanocoumarin compound, exhibits 
antibacterial, antioxidant activity21 and topoisomerase II 
inhibitor activity22.  It is estimated by different analytical 
methods such as HPLC 16 and HPLC-MS23.  
Bakuchiol a meroterpenoid phenol present in the seeds of 
Psoralea corylifolia is yellow coloured liquid. It exhibits 
different biological activities such as antitumor24, 
antimicrobial25, antibacterial 26,27, hepatoprotective and DNA 
polymerase inhibitor activity22. HPLC 14, 16, GC28 and GC-MS29 
methods have been reported for the estimation of Bakuchiol.  
  
Recently, the number of commercial herbal formulations of 
Bakuchi are available for various treatments such as 
psoriasis, vitiligo, leprosy etc. The major problem with any 
medicines is their oral bioavailability and stability. In the 
gastrointestinal tract, drug molecules are exposed to acidic 
and alkaline pH and digestive juice containing enzymes such 
as pepsin and pancreatin. This may sometimes lead to 
degradation of such compounds, hence interfere with the 
absorption thereby bioavailability. There is no data available 
to provide insight into the stability of psoralen, bakuchicin 
and bakuchiol in gastrointestinal system. Moreover the 
herbal formulations are needed to be standardized to ensure 
their safety and efficacy. Hence the present study aimed to 
establish the effect of pH and enzymes on psoralen, 
bakuchicin and bakuchiol using simulated physiological 
fluids at 37°C and to standardize the herbal formulations of 
Bakuchi with respect to the above marker components. 
Although a HPLC method is reported for the simultaneous 
estimation of the above components, it is either tedious or 
time consuming method.  Nowadays HPTLC is becoming a 
routine analytical technique because of its advantages of low 
operating cost, high sample throughput, simplicity, and 
speed, the need for minimum sample clean up, 
reproducibility, accuracy, reliability, and robustness. The 
literature survey revealed that there is no method available 
yet to simultaneously estimate psoralen, bakuchicin and 
bakuchiol by HPTLC. In light of these all observations it was 
decided to develop a validated HPTLC method for 
simultaneous estimation of psoralen, bakuchicin and 
bakuchiol. The method was applied to study the effect of pH 
and GI enzymes on these three components in simulated 
gastro- intestinal fluids. In addition the method was 
successfully applied for the standardization of mono and 
polyherbal formulations containing Psoralea corylifolia Linn. 
 
2. EXPERIMENTAL 
2.1 Materials and reagents 
Crude plant powder of Psoralen, Bakuchicin and Bakuchiol 
was obtained from the Ayurvedic Aaushadhalaya, local 
market of Pune, India. The formulation containing Psoralea 
corylifolia was procured from the local market and 
designated as MF1 and MF2.   
Reference standards Psoralen (>96%), Bakuchicin (>96%), 
and Bakuchiol (>95%) obtained from Natural Remedies pvt 
ltd, Bangalore, India were used. All chemicals and reagents 
used were of analytical grade. 
         2.2 Preparation of standard solutions 
Standard stock solution of Psoralen, Bakuchicin and 
Bakuchiol (1000µg/mL) was prepared by dissolving 1 mg 
each of accurately weighed markers in methanol and making 
up the volume to 1 mL with methanol. Sample solutions 
were prepared by dilution of the stock solution with 
methanol to reach a concentration range of 10 - 120 µg/mL, 
20 - 130 µg/mL, and 40-320 µg/mL  for Psoralen, Bakuchicin 
and Bakuchiol  respectively. The complete dissolution of the 
markers was ensured by ultrasonication for 15 minutes. One 
microlitre of each sample solution was applied on HPTLC 
plates to obtain the final concentration of 10-120 ng spot-1, 
20 - 130 ng spot-1 40-320  ng spot-1 for   Psoralen, Bakuchcin 
and Bakuchiol  respectively.  
2.3 Chromatographic conditions:  
Standard and sample solutions were applied to the plates by 
means of a Camag (Muttenz, Switzerland) Linomat V 
automated spray-on band applicator equipped with a 
100.00-μL syringe (Hamilton) and operated with the settings 
of band length 6 mm, application rate 10 s μL−1, distance 
between bands 12 mm, distance from the plate edge 10 mm, 
and distance from the bottom of the plate 10 mm. Plates 
were developed to 8 cm beyond the origin with n-Hexane:  
Ethyl acetate ( 7.5: 2.5 v/v)  as mobile phase in twin trough 
glass chambers after saturation of the chamber with mobile 
phase vapour for 30 min (the optimum chamber-saturation 
time) at room temperature. After development, mobile 
phase was evaporated from the plate by use of an air-dryer 
for 10 min. Densitometric scanning was then performed in 
absorbance mode at 285 nm for Psoralen, Bakuchicin and 
Bakuchiol using the deuterium lamp as the source of 
radiation. A Camag model III TLC scanner linked with CATS 
(V 3.5, Camag) integration software was used. The slit 
dimensions were 5 mm × 0.45 mm and the scanning speed 
10 mm s−1. Calibration was performed by triplicate 
application of 1.0–10.0 μL of mixed stock standard solution, 
resulting in 20–120 ng per band for  Psoralen, 30–130 ng per 
band for Bakuchicin and 120-320 ng per band for Bakuchiol. 
Peak area and concentration data were treated by linear 
least-squares regression analysis. The amounts of Psoralen, 
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respective calibration plots obtained by plotting the 
concentration of standard against peak area.    
2.4 Validation of the method 
The proposed method was validated for specificity, linearity, 
precision, accuracy and robustness following the ICH 
guidelines 30, 31, 32.  
2.4.1 Linearity, LOD and LOQ 
Linearity was determined by construction of calibration 
plots and linear least-squares regression analysis as 
described above. The limit of detection (LOD) and limit of 
quantification (LOQ) were determined by diluting known 
concentrations of standard stock solution until the average 
responses were approximately three (For LOD) or ten times 
(for LOQ) the responses of the blank. Six replicate 
determinations were performed using methanol alone as 
blank.  
2.4.2 Precision 
Precision study was carried out for the repeatability of 
sample application and measurement and the result was 
expressed as % RSD of peak areas. Variability of the method 
was studied by analyzing aliquots of standard solutions of 
Psoralen (20, 40, 60, 80, 100, 120 ng/spot), Bakuchicin (30, 
50, 70, 90,110,130 ng/spot) and Bakuchiol 
(120,160,200,240,280,320 ng/spot) on the same day (intra-
day precision) and on different days (inter-day precision), 
and the results were expressed as % RSD.   
2.4.3. Robustness 
Robustness of the method was checked by making 
intentional changes in the parameters. Small change in the 
mobile phase composition was tried (Formic acid ± 0.01 ml). 
The amount of mobile phase and temperature were varied in 
the range of ± 5%. The plates were prewashed with 
methanol and activated at 60oC ± 5 for 5, 10, 15 min 
respectively prior to chromatography. Time from spotting to 
chromatography and from chromatography to scanning was 
varied from 0, 30, 60 and 90 min. Robustness  was done at 
three different concentration levels  40, 80, 120 ng spot-1 for 
psoralen , 50, 90, 130 ng spot-1 for bakuchicin and 160, 240, 
320 ng spot-1  for bakuchiol respectively.  
2.4.5. Specificity 
The identity of the spot of the markers in sample was 
confirmed by comparing the Rf and spectra of the spot with 
that of the standard.  
2.4.6.Accuracy 
The accuracy of the method was tested by performing 
recovery studies at three levels (80, 100, and 120% standard 
addition).  The amount of markers present in the 250 mg of 
the crude extracts was determined from the regression 
equation. Known amount of the standard was added at three 
levels and recovery was found. The percent recovery as well 
as the average percent recovery was calculated. 
2.4.7. Stability in sample solution   
Solutions of two different concentrations of 100 and 200 
ng/spot for Psoralen, Bakuchicin and Bakuchiol and  were 
prepared from sample solution, stored at room temperature 
for 0.5, 1.0, 2.0, 4.0 and 24 hr and analysed. 
 
 
2.4.8. Spot Stability  
Two-dimensional chromatography using the same solvent 
system was applied to find out any decomposition occurring 
during spotting and development.  
2.5. Stability studies of Psoralen, Bakuchicin and 
Bakuchiol in simulated physiological fluids 
 Degradation of psoralen, bakuchicin and bakuchiol was 
investigated in both simulated gastric (SGF) and intestinal 
fluid (SIF). 0.2 ml of sample solution each of psoralen, 
bakuchicin and 0.4 ml of bakuchiol was added to SGF and SIF 
and diluted to 1ml with SGF and SIF. SGF and SIF were 
prepared as per USP procedure [33]. The solution was 
incubated and maintained at 370C for up to 72 hrs. Samples 
were taken at specified time intervals and analyzed by 
HPTLC. 
2.5.1. Effect of pH on Psoralen, Bakuchicin and Bakuchiol  
 Effect of pH   on Psoralen, Bakuchicin and Bakuchiol was 
studied at pH 1.2 and 6.8 at 370c. The same procedure was 
followed to prepare sample solutions as mentioned above 
excluding the gastric and intestinal enzymes. 
2.6.  Estimation of Psoralen, Bakuchicin and Bakuchiol 
in crude powder 
500 mg of the powder of plant materials was extracted 
separately with (4x25) ml of methanol by ultrasonication for 
45 min. The pooled extracts of samples were concentrated 
transferred to 10 mL volumetric flask and the volume was 
made up with methanol. The extract was centrifuged at 5000 
rpm for 10 min and the supernatant was filtered through a 
0.45 μm filter membrane before chromatographic analysis 
and analysed for drug content. The analysis was repeated six 
times. 
2.7. Analysis of commercial formulations 
To determine the content of Psoralen, Bakuchcin and 
Bakuchiol in tablets of mono and polyherbal formulation, the 
contents of twenty tablets of both formulations were 
weighed, their mean weight determined and were finely 
powdered. The weight of powder equivalent to tablet 
content was transferred into a 50 mL volumetric flask 
containing 25 mL methanol, sonicated for 45 min and 
diluted to 50 mL with methanol. The resulting solution was 
centrifuged at 3000 rpm for 15 min and supernatant was 
analyzed for the said markers. 10 µL of the filtered solution 
was spotted on the HPTLC plate followed by development 
and scanning. 
3. RESULTS AND DISCUSSION 
3.1. Optimization of chromatographic conditions 
Initially, mobile phase was selected on the basis of previous 
reports of psoralen 11 consisting of toluene, ethyl acetate, 
and methanol. After several trails, replacement of toluene 
with n-hexane was found to be suitable for the movement of 
all three markers. Finally mobile phase consisting of n-
Hexane: Ethyl acetate (7.5: 2.5 v/v) was found to give 
desirable Rf value. The optimized mobile phase can able to 
give symmetrical, well-resolved reproducible peaks with 
good shape and baseline separation. The Rf values obtained 
were 0.37, 0.48 and 0.63 for Psoralen, Bakuchicin and 
Bakuchiol respectively (Fig.2). The identities of the bands 
from the sample extracts and commercial formulations were 
confirmed by overlapping the densitograms of standard with 
that of samples (Fig. 3). 
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Fig. 2: Densitogram of standard Psoralen, Bakuchicin and Bakuchiol 
Peak  1:  Psoralen           Peak  2:  Bakuchicin         Peak  3:  Bakuchiol 
 
Fig 3: Spectral overlay of Psoralen, Bakuchicin and Bakuchiol 
 
3.2. Validation of the method 
The linear regression data (Table 1) showed a good linear 
relationship over a concentration range of 20-120 ng spot-1 
(r2 = 0.998) for Psoralen , 30-130 ng spot-1 (r2 = 0.998) for 
Bakuchicin and 120-320 ng spot-1 for Bakuchiol ((r2 = 
0.999). The signal: noise ratios of 3:1 and 10:1 were 
considered as LOD and LOQ respectively. The limit of 
detection (LOD) and the limit of quantitation (LOQ) were 
found to be 10 ng spot-1 and 20 ng spot-1 for Psoralen, 20 ng 
spot-1  and 30 ng spot-1  Bakuchicin , 80 ng spot-1  and 120 ng 
spot-1 for Bakuchiol  respectively. The repeatability of the 
sample application and measurement of peak area were 
expressed as % RSD and found to be 1.28 and 1.21, 1.62 and 
1.67, 1.45 and 1.75 for  psoralen,  bakuchicin  and bakuchiol 
respectively. The results of intermediate precision 
experiments are shown in (Table 2). The developed method 
was found to be precise as the RSD values for repeatability 
and intermediate precision studies were < 2%, respectively 
as recommended by ICH guidelines.  
Separation of the drug was found to be similar when 
analyses were performed using different chromatographic 
system on different days. For robustness analysis, the 
standard deviation of peak areas was calculated for each 
parameter and % RSD was found to be less than 2%. The low 
values of %RSD as shown in (Table 3) indicate the method 
was robust. The accuracy of the method was checked by 
standard addition method. The results were presented in 
(Table 4). The percentage recovery obtained was 99.39%, 
99.68% and 99.85% for psoralen, bakuchicin and bakuchiol 
respectively. The average percentage value and low RSD 
value demonstrate the reliability and reproducibility of the 
proposed method for tablets. 
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Table 1:  Linear regression data for the calibration curves 
PARAMETERS PSORALEN BAKUCHICIN BAKUCHIOL 
Linearity range 20-120  ng/spot 
 
30-130  ng/spot 120-320 ng/spot 
r2 0.998 0.998 0.999 
Slope ± S.D* 38.36 ± 0.6881 32.99 ± o.7078 11.30 ± 0.1394 
Intercept ± S.D 84.77 ± 53.59 -53.70 ± 61.57 -593.7 ± 32.12 
Confidence limit of slopea 36.45 to 40.27 31.03 to 34.95 10.91 to 11.69 
Confidence limit of intercept* -64.01 to 233.5 -224.6 to 117.2 -682.8 to -504.5 
Sy.x 57.57 59.22 23.33 
*p<0.001 - Slope significantly different from zero 
a95% confidence limit. 
Sy.x- Standard deviation of residuals from line. 




Conc. ± SD 
RSD (%) Interday Found 
Conc. ± SD 
RSD (%) 
PSORALEN 40 39.95 ± 0.087 0.217 40.18 ± 0.323 0.804 
80 80.75 ± 0.608 0.753 80.69 ± 0.512 0.634 
120 119.75 ± 1.581 1.320 120.47 ± 0.630 0.520 
BAKUCHICIN 50 49.94 ± 0.264 0.528 49.60 ± 0.633 1.277 
90 90.48 ± 1.244 1.376 90.64 ± 1.184 1.307 
130 131.08 ± 1.926 1.469 130.92 ± 1.668 1.274 
BAKUCHIOL 160 157.20 ± 1.263 0.804 156.08 ± 1.905 1.221 
240 232.00 ± 4.542 1.958 233.84 ± 3.522 1.506 
320 324.83  ± 5.360 1.650 325.49 ± 4.519 1.388 
 
Table 3:  Robustness of the method 
PARAMETER SD of peak area % RSD a 
Psoralen Bakuchicin Bakuchiol Psoralen Bakuchicin Bakuchiol 
Mobile phase composition 
(formic acid ± 0.01 ml) 
1.760 1.125 1.538 0.758 0.653 0.225 
Amount of mobile phase 
(±5%) 
1.556 1.378 1.265 0.164 0.835 0.325 
Time from spotting  to 
chromatography 
1.558 1.621 1.823 0.435 0.651 0.539 
Time from chromatography 
to scanning 
1.643 1.059 1.238 0.139 0.589 0.325 
Temperature (±5%) 1.258 1.151 1.089 0.248 0.543 0.158 
Plate pretreatment 1.116 1.119 1.253 0.135 0.765 0.251 
 a  n = 6,  Average of three concentrations 40, 80, 120 ng spot-1 for Psoralen and 50, 90, 130 ng spot-1 for Bakuchicin and 160, 
220, 340 ng spot-1  for Bakuchiol 
Table 4:  Recovery studies 
Compound 
(  µg)  
Amount added   
(%) 
Total Amount   
(µg) 
Amount found*  
(µg) 
Recovery       
(%) 




80 134.46  133.5 ± 4.50 99.29 ± 0.05 99.39 
100 149.4  148.2 ± 9.01 99.19 ± 0.10 
120 164.34  163.84 ± 7.21 99.69 ± 0.28 
BAKUCHICIN 
128 
80 230.4  229.5 ± 5.50 99.60 ± 0.03 99.68 
100 256  255.66 ± 3.05 99.86 ± 0.04 
120 281.6  280.4± 4.56 99.57± 0.08 
BAKUCHIOL 
2225 
80 4005  3995 ±6.89 99.75 ± 0.12 99.85 
100 4450  4446± 4.08 99.91 ± 0.04 
120 4895  4889.66±6.11  99.89 ± 0.06 
*Mean ± Standard deviation (n=3) 
 
3.3. Stability in sample solution 
No additional peak was found in the chromatogram showed 
that the compounds are stable in sample solutions after 
storage of 24 hours. 
 
3.4. Spot Stability  
This was analysed by two dimensional chromatography. In 
case, if decomposition occurs during development, peak(s) of 
decomposition product(s) shall be obtained for the analyte 
both in the first and second direction of the run. No 
decomposition was observed ensure the spot stability. 
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3.5 Effect of pH (1.2) on marker components  
 The effect of pH on Psoralen in SGF at PH 1.2 was 
investigated at 370c. There was no change in the peak area 
observed for Psoralen. Psoralen was found to be most stable 
component where as slight degradation (4.18 %) of 
Bakuchiol was observed after 40 min. The Rf value of 
additional peak was found to be 0.62 [Fig. 7]. Bakuchicin was 
degraded completely in SGF at 370c within 3 min. 
3.6. Effect of pH (6.8) on marker components  
 In SIF at 370c, Psoralen was found to be the most stable 
component whereas bakuchicin was degraded within 3 min.  
Bakuchiol was found to be stable up to 72 hrs.  
3.7. Effect of pepsin enzyme on marker components 
at pH 1.2 
 The effect of pepsin enzyme on psoralen in SGF at pH 1.2 
was investigated at 370c.There was no change in the peak 
area of psoralen and thus psoralen was considered to be 
most stable component. Bakuchicin was degraded 
completely within 3 minutes in SGF at pH 1.2. Slight 
degradation of bakuchiol (7.437 %) was observed in SGF at 
pH 1.2. The Rf value of additional peak was found to be 0.57 [ 
Fig. 8].  
3.8. Effect of pancreatin enzyme on marker 
components at pH 6.8 
There was no additional peak observed for psoralen in SGF 
at pH 6.8. There was no effect of pancreatin on psoralen in 
SGF at pH 6.8 and thus it was found to be stable. Bakuchicin 
was degraded within 3 min whereas Bakuchiol was found to 
be stable up to 72 hrs.  
3.9. Analysis of the commercial formulations and Crude 
extract 
Analysis of the amount of Psoralen, Bakuchicin and 
Bakuchiol studied application of the developed method in 
crude extracts and commercial tablets, using the regression 
equation mentioned above. The content of Psoralen, 
Bakuchicin and Bakuchiol with % R.S.D were found to be 
0.292 ± 0.0587 ,  0.355 ± 0.0651  and 3.499 ± 0.9482  in 
crude extract, 0.124 ± 0.017, 0.255 ± 0.013, 4.330 ± 0.106, in 
monoherbal formulation and  0.2 91 ± 0.012 , 0.462 ± 0.0693  
and   7.73  ± 1.6476  in polyherbal formulation respectively 
(Table 5). The densitograms of crude extract, mono herbal 
and poly herbal formulations were shown in Fig. 4, 5 and 6 
respectively. 
Table 5: Estimation of drug content in samples 
 Samples Drug content * (% w/w ) 
PSORALEN BAKUCHICIN BAKUCHIOL 
Crude extract 0.292 ± 0.0587 0.355 ± 0.0651 3.499 ± 0.9482 
MF1 0.2 91 ± 0.012 0.462 ± 0.0693 7.73  ± 1.6476 
MF 2 0.124 ± 0.017 0.255 ± 0.013 4.330 ± 0.106 
*Mean ± Standard deviation (n=3) 
Table 6:  Summary of the validation parameters 
Parameter Psoralen Bakuchicin Bakuchiol 
Precision (%RSD) 1.32 0.53 0.80 
Repeatability of Application (n= 7) 1.28 1.62 1.45 
Repeatability of Measurement (n= 7) 1.21 1.67 1.75 
Limit of Detection (ng) 10 20 80 
Limit of Quantification( ng) 20 30 120 
Specificity Specific Specific Specific 
Linearity (Correlation coefficient) 0.998 0.998 0.999 
Range ( ng/spot) 20-120 30-130 120-320 
Robustness Robust Robust Robust 
 
 
Fig. 4: Densitogram of crude drug 
Peak 6: Psoralen     Peak 7: Bakuchicin    Peak 8: Bakuchiol 
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Fig. 5: Densitogram of polyherbal formulation 
Peak 6: Psoralen    Peak 7: Bakuchicin              Peak 8: Bakuchiol 
 
Fig 6: Densitogram of monoherbal formulation 
Peak 1 : Psoralen            Peak 2: bakuchicin           Peak 3 : bakuchiol 
 
Fig: 7 Densitogram of stability of bakuchiol in simulated gastric fluid in absence of   pepsin enzyme 
Peak 1: degradation peak          Peak 2: standard bakuchiol peak 
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Fig: 8 Densitogram of stability of bakuchiol in simulated gastric fluid in presence of pepsin enzyme 
Peak 1: degradation peak   Peak 2: standard bakuchiol peak 
 
4. CONCLUSIONS 
We established a HPTLC method for the simultaneous 
estimation of the constituents Psoralen, Bakuchicin and 
Bakuchiol. The proposed method was found to be suitable 
for estimation of these markers in polyherbal formulations 
as it is proved to be precise, reproducible, reliable, accurate 
and robust. In addition the method was successfully applied 
for the in vitro stability studies of these compounds in 
physiological fluids. The study revealed that the DNA 
polymerase inhibitors bakuchicin and bakuchiol are not 
stable in the acidic pH which may lead to poor 
bioavailability.  
REFERENCES 
1) Quio CF, Han QB, Song JZ, Mo SF, Kong LD, kung HF. Chem 
Pharm Bull. 2006;54:  887-90.    
2) Khare CP. Encyclopedia of Indian Medicinal Plants. New York: 
Springer-Verlag 2004; 384-386.      
3) Sah P., Agrawal D., Garg SP. Indian J Pharma Sci.  2006; 68: 768-
771.  
4) Khushboo PS, Jadhav VM,   Kada VJ, Sathe NS, "Kushtanashini", 
2010; 4(7): 69-76.  
5) Anonymous, Medicinal plants of India. Indian council of medical 
research, New Delhi; 1987: 518-530. 
6) Anand KK, Sharma ML, Singh B, Ghatak BJR. Indian J. Exp. Biol. 
1978; 16(11): 1216- 1217.     
7) Chopra RN, Chopra IC. Indigenous Drugs of India, Kolkata, 
Academic Publishers 1958; 2: 391-394.  
8) Panda H. Herbs: Cultivation and medicinal uses, New Delhi: 
National Institute of Industrial Research 2000 : 479-481.   
9) Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Boca 
Raton, Florida: CRS Press, 2001: 274-275.  
10) Sharma PC, Yelne MB, Dennis TJ. Database on medicinal plants 
used in Ayurveda, New Delhi: Central Council for Research in 
Ayurveda and Siddha 2001; 2:  89-93.  
11) Gupta AK, T Neeraj, S Madhu. Quality Standards of Indian 
Medicinal Plants, New Delhi: ICMR  2005; 3: 290-298.  
      12) Tiwari A, Bhakuni RS.  Indian Journal of Chemistry 2010;  49B: 
256-259.  
      13) Ruan B, kong LY, Takaya Y, Niwa M. Journal of Sian Natural 
Products Research,  2007;  9(1): 41-44.  
      14) Lin C-F, Linghuang Y, Chien M-Y,  Shen S-J, Chen C-C.  Journal of 
Food and Drug Analysis (2007); 15(4): 433-437.  
      15) Dong N T, Bae K, Kim Y H, Hwang G S, Heo O S, Kim S E. Arch 
Pharm Res. 2003; 26(7): 516-520.   
      16) Murali B., Amit A, Anand M S, Venkataraman B V.  Journal of 
Natural Remedies 2002; 20(2): 277-282.   
      17) Ali J, Akhtar N, Sultana Y, Baboota Sv, S Ahmad, Acta 
Chromatographia 2008; 20(2): 277-282.  
      18] Nidhi Dubey, Nitin Dubey, R Mehta, AK Saluja, Journal of AOAC 
2004; 92(3): 779-784.       
      19) D Wang, H Yang, H Englehardt, H Zhang, Electrophoresis 1999; 
20: 1895-1899.   
      20) W Yang, C Fenq, D Kong, X Shi, Y Cui, M Liu, Q Wang, Y Wang,  L 
Zhang, J Chromatogr B Analyt Technol, Biomed Life Sci. 2010: 95-
96.  
      21) E Souri, H Farsam, P Sarkheil, F Ebadi, Pharmaceutical Biology 
2004; 42(6): 396-399.  
      22) Sun Nan Jun, Woo Sung Hoo, Cassady J M, Snapka R M, J. Nat. 
prod. 1998; 61:362-366.       
      23) S Manimegalai, T Rajeswari, R Shanmugam, G Rajalakshmi, 
Journal of Biopesticides 2010; 3(1): 242-245.  
      24) Ryu S Y, Choi S U, Lee C O, Zee O P, Arch. Pharm. Res. 1992; 
15(4): 356-359.   
      25) H Katsura, RI Tsukiyama, A Suzuki, M Kobayashi, Antimicrobial 
agents and Chemotherapy 2001; 45(11): 3009-3013.   
      26) P J Hsu, J S Miller, J M Berger, Natural Product Research 2009: 
781-788.  
      27) N A khatune, E Islam, E Haque, P Khondkar, M Mukhlesur, 
Fitoterapia  2004; 75:228-230.       
      28) S Yao, B Yang Z Xu, Zhongguo Zhong Yao Za Zhi) 1995; 
20(11):681-683.    
      29) H Seedi, M Zayed, S Roshdy, M salem, M Hawata, F Essawy, M 
Barbary, S Kousy, Medicinal Chemistry Research 2009. 
      30) ICH, Q2A Validation of Analytical Procedure: Methodology, 
International Conference on Harmonization, Geneva, October 
1994.  
      31) ICH, Q2B Validation of Analytical Procedure: Methodology, 
International Conference on Harmonization, Geneva, March 1996.   
      32) ICH Guidance on Analytical Method Validation, International 
Convention on Quality for the Pharmaceutical Industry, Toronto, 
Canada, September 2002. 
      33) United states of pharmacopeia- NF. Asian edition 2005: 2858. 
  
